Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.

BACKGROUND: When treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonly add a second antipsychotic, despite the lack of robust evidence to justify this practice. OBJECTIVES: The main objectives of the study were to establish the clinical effect...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Health Technol Assess
Autors principals: Barnes, Thomas Re, Leeson, Verity C, Paton, Carol, Marston, Louise, Davies, Linda, Whittaker, William, Osborn, David, Kumar, Raj, Keown, Patrick, Zafar, Rameez, Iqbal, Khalid, Singh, Vineet, Fridrich, Pavel, Fitzgerald, Zachary, Bagalkote, Hemant, Haddad, Peter M, Husni, Mariwan, Amos, Tim
Format: Artigo
Idioma:Inglês
Publicat: NIHR Journals Library 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5601255/
https://ncbi.nlm.nih.gov/pubmed/28869006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta21490
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars